Trial
NCT04498325
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
NeoImmuneTech
Condition
COVID-19
Intervention
NT-I7
Why stopped
Principal investigator is leaving the institution.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-05